Recombinant Human VEGF-A/VEGF165 (C083)

目录 规格 价格
【VEGF165产品说明】:
Recombinant Human Vascular Endothelial Growth Factor A is produced by our Mammalian expression system and the target gene encoding Ala27-Arg191 is expressed.
【VEGF165质量控制】:
Greater than 95% as determined by reducing SDS-PAGE.
【VEGF165制剂】:
Lyophilized
【VEGF165保存】:
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
【VEGF165复溶】:
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
【关于VEGF165】:
Human Vascular endothelial growth factor (VEGF), also known as VEGF-A and vascular permeability factor (VPF), belongs to the platelet-derived growth factor family of cysteine-knot growth factors. It is a potent activator in vasculogenesis and angiogenesis both physiologically and pathologically. VEGF-A has 8 differently spliced isoforms, of which VEGF165 is the most abundant one. VEGF165 is a disulfide-linked homodimer consisting of two glycosylated 165 amino acid polypeptide chains. VEGF stimulates the cellular response through binding to tyrosine kinase receptors VEGFR1 and VEGFR2 on the cell surface. It is widely accepted that VEGFR2 mediate almost all of the known cellular responses to VEGF while the function of VEGFR1 is less defined and is thought to modulate the VEGFR2 signaling.
参考文献

  • Ren X, Li J, Xu X(任心怡,程远国).
    IBI302, a Promising Candidate for AMD Treatment, Targeting Both the VEGF and Complement System with High Binding Affinity in vitro and Effective Targeting of the Ocular Tissue in Healthy Rhesus Monkeys.
    Experimental eye research(2016)
For research use ONLY.